ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo investigate the therapeutic mechanism of
methodsThirty MRL/lpr lupus mice were randomly divided into model group, JPZS treatment group, and prednisone treatment group, with 10 C57BL/6 mice as the control group. After treatment with daily gavage with normal saline, JPZS (7.8 g/kg) or prednisone (5 mg/kg) for 8 consecutive weeks, the mice were examined for changes in serum levels of anti-ds DNA, C3 and Scr, 24-h urine protein (24hPRO) and renal Fe
resultsCompared with the normal control mice, the mouse models of SLE had significantly elevated levels of dsDNA, Scr, 24hPRO, Fe²⁺, MDA, and ROS, increased renal expressions of p53, MDM2, ACSL4, Bax, and caspase-3, lowered levels of C3, SOD, and GSH, and reduced renal expressions of GPX4, SLC7A11, and Bcl-2 at both the mRNA and protein levels. Treatment with JPZS and prednisone both significantly ameliorated these abnormalities in the mouse models.
conclusionsJPZS can reduce renal ferroptosis in lupus mice, ameliorate kidney injury, and promote renal function repair possibly by inhibiting the p53-MDM2 signaling axis, which is closely associated with regulation of glomerular podocyte ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.